Last reviewed · How we verify
T cell vaccination
T cell vaccination is a Biologic drug developed by Hadassah Medical Organization. It is currently in Phase 3 development for Treatment of various types of cancer.
T cell vaccination stimulates the body's immune system to recognize and attack cancer cells.
Researchers have been studying T cell vaccination in various conditions, including COVID-19, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, and HIV Infections, using different interventions such as the hAd5-S-Fusion+N-ETSD vaccine and CD19.CAR-multiVST. The concept of T-cell vaccination involves immunizing against autoreactive T cells, which is analogous to classical vaccination against infectious diseases, but targets a pathogenic T-cell population instead.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | T cell vaccination |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the introduction of antigens from cancer cells to T cells, which then recognize and target these cells for destruction. The goal is to induce a long-term immune response against cancer cells.
Approved indications
- Treatment of various types of cancer
Common side effects
- Injection site reactions
- Fatigue
- Pain
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (PHASE1)
- Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (PHASE2)
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies (PHASE1)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T cell vaccination CI brief — competitive landscape report
- T cell vaccination updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI
Frequently asked questions about T cell vaccination
What is T cell vaccination?
How does T cell vaccination work?
What is T cell vaccination used for?
Who makes T cell vaccination?
What development phase is T cell vaccination in?
What are the side effects of T cell vaccination?
Related
- Manufacturer: Hadassah Medical Organization — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of various types of cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing